Pfizer: $1.5bn Of Blackstone Funding Doesn't Make Berobenatide A Winning Obesity Drug

🇺🇸 Seeking Alpha (US) —
Pfizer: $1.5bn Of Blackstone Funding Doesn't Make Berobenatide A Winning Obesity Drug

AI Summary

The article argues that $1.5 billion in Blackstone funding does not make Pfizer's obesity-drug candidate berobenatide a likely winner. It evaluates the drug's commercial prospects and the implications of the funding, though the supplied text offers no supporting details.

Markets Deals Health Pfizer Blackstone berobenatide obesity drug biopharma funding drug prospects

Read original source →